USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
16 Aug 2022 | 02:45 PM GMT

Sustainable Business Models for DTx

Anchored by:

Elena Mustatea
CEO
BOLD HEALTH
Rick Bartels
President/Founder
DTXCC

Participants:

Elena Mustatea CEOBold Health
Elena Mustatea
CEOBold Health
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC
Adriano Garcez Director, DTx/SaMD Evidence GenerationZS Associates
Adriano Garcez
Director, DTx/SaMD Evidence GenerationZS Associates
Arthur Bretonnet Global Digital Innovation LeadUCB Pharma
Arthur Bretonnet
Global Digital Innovation LeadUCB Pharma
David Faria Digital InnovationAbbott
David Faria
Digital InnovationAbbott
Dr. Nick (Nemanja) Kovacev Head of Healthcare and Life Sciences PracticeHTEC Group
Dr. Nick (Nemanja) Kovacev
Head of Healthcare and Life Sciences PracticeHTEC Group
Steve Kimm SVP - Strategy and OperationsAddressable Health
Steve Kimm
SVP - Strategy and OperationsAddressable Health

About this Meeting

It is one of the key questions that every digital therapeutic (DTx) company must answer - what business model will set them up for success in the long run? The answer, however, has proved tricky, with many potential routes, but few certainties.  

Finding the right commercialisation model to scale in a sustainable way can be challenging, so we will break down the different approaches and what might prove the most effective for different DTx products.  

Join us to discuss:  
  • Business-to-business (B2B), business-to-consumer (B2C) or a bit of both? What are the trade-offs between approaches and how can companies prioritize?  
  • Without a one-size-fits-all approach, how can companies test different business models at the same time to understand what model sticks?  
  • How can companies tailor the approach to different geographics, type of product and therapeutic areas? How can they target the different types of payers, pharma partners, providers, etc?  
  • Pricing is vital, regardless of the route to market. How can companies be smart about price anchors to maximize both adoption and commercial viability?  
  • What evidence is required to pursue different market access routes and how can companies plan their proof points for both short and long term success?